Paradigm PPS nasal spray to treat Allergic Rhinitis
Filed with ASX · · 3 pages · English
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Shareholders Update
- ASX Admission Market Release
- Paradigm Secures Key US Patent
- Paradigm Biopharmaceuticals Receives Ethics Approval
- Paradigm starts Clinical Trial
Later from Paradigm Biopharmaceuticals
- Preliminary Final Report
- Paradigm PPS a potential in the treatment of viral arthritis
- Preclinical study underpins efficacy of Paradigms RhinosulR
- Paradigms Placement heavily oversubscribed
- Appendix 4C - September 2016 quarter
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals